ArticleJournal of clinical laboratory analysis2022
The prevalence of multiple drug resistance Escherichia coli and Klebsiella pneumoniae isolated from patients with urinary tract infections.
Article in Journal of clinical laboratory analysis, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it, 71 citations in OpenAlex.
- Cranberry-derived bioactives for the prevention and treatment of urinary tract infections: antimicrobial mechanisms and global research trends in nutraceutical applications.Frontiers in nutrition · 2025Pooled it
- Genomic and phenotypic characterization of Klebsiella pneumoniae phage KP Ø1: a novel lytic Slopekvirus targeting uropathogenic multidrug-resistant Klebsiella pneumoniae.Scientific reports · 2026Article
- Biofilm-Forming Capacity andAntibiotics (Basel, Switzerland) · 2026Article
- Antibiotic resistance profiles and co-occurrence of ESBL and AmpC β-lactamase genes in ESBL-producing Gram-negative bacteria of clinical origin.BMC microbiology · 2026Article
- Integrated analysis of global regulators and efflux genes associated with antimicrobial resistance reversal in multidrug resistant Klebsiella pneumoniae.Scientific reports · 2026Article
- Epidemiological characteristics and antibiotic resistance of pathogens in urinary tract infection in Chengdu 2019-2023, China.BMC microbiology · 2026Article
- Determinants of multidrug-resistant urinary tract infections: A retrospective cross-sectional study from a tertiary care hospital in southern Bangladesh.PLOS global public health · 2026Article
- Drug Resistance Patterns and Pathogen Distribution in Patients with Urinary Tract Infection in Suzhou, China: A Five-Year Retrospective Study (2020-2024).Infection and drug resistance · 2026Article
- Analysis of Antimicrobial Use and Bacterial Susceptibility in Patients with Urinary Tract Infections at a Certain Hospital From 2021 to 2023: A Retrospective Cohort Study.International journal of general medicine · 2026Article
- Trends and correlations of infection rates and drug resistance of Escherichia coli among ICU and Non-ICU patients in Guizhou, China.PloS one · 2026Article
- Detection of AcrAB efflux pump mediated ciprofloxacin resistance in Escherichia coli and Klebsiella pneumoniae in Nepal.BMC infectious diseases · 2025Article
- Phylogenetic analysis ofIranian journal of microbiology · 2025Article
- Article
- Extended-Spectrum Beta-Lactamase Production and Carbapenem Resistance in Elderly Urinary Tract Infection Patients: A Multicenter Retrospective Study from Turkey.Antibiotics (Basel, Switzerland) · 2025Article
- Urinary Tract Infections Caused byMicroorganisms · 2025Article
- Analysis of the Distribution Characteristics and Changes of Drug Resistance of Pathogens in Patients with Urinary Tract Infection Across Southwest China From 2019 to 2023.Infection and drug resistance · 2025Article
- High prevalence of multidrug-resistant and ESBL-producing bacteria in a primary healthcare facility in Accra, Ghana: A cross-sectional study.PLOS global public health · 2025Article
- Global burden of urinary tract infections in older women from 1990 to 2021 with projections to 2040: a trend analysis of the Global Burden of Disease Study 2021.Frontiers in cellular and infection microbiology · 2025Article
- Modern Solutions to UTIs: The Role of Nanotechnology and Herbal Treatments.Current drug targets · 2025Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundUrinary tract infections (UTIs) and bacterial resistance to antibiotics is global health problem and a threat to public health in many countries.
aimsThe study aimed to determine the prevalence of MDR Escherichia coli and Klebsiella pneumoniae in UTI patients. MATERIALS &
methodsThe midstream urine samples of 120 patients were collected and cultured as described by the protocols at the respective sample collection sites on MacConkey Blood agar. Samples were tested by using the fully automated VITEK 2 Compact system for Gram-negative identification and detection of antimicrobial susceptibility of microorganisms.
resultsThe most prevalent pathogen was E. coli, which was found in 82 (68.3%) urine samples, followed by K. pneumonia, found in 38 (31.7%) urine samples. As far as antibiotic resistance is concerned, E. coli isolates were found to be highly resistant for ceftriaxone (89.0% of the isolates), ampicillin (86.6%), levofloxacin (82.9%), cefotaxime (79.3%), aztreonam (74.4%), ceftazidime (68.3%) and gentamicin, piperacillin, and trimethoprim-sulfamethoxazole, 54.9 and 53.7%, respectively. The E. coli isolates were found to be relatively less resistant to imipenem (2.4%), cefepime (34.1%), and ciprofloxacin (35.4%). For K. pneumonia isolates, high resistance rates were observed for piperacillin (81.6%), levofloxacin (78.9%), ampicillin (76.3%), cefotaxime (73.7%), trimethoprim-sulfamethoxazole (71.1%), ceftazidime (65.8%), gentamicin (63.2%), cefepime (50.0%), and aztreonam (44.7%). However, moderate resistance rates were detected for these were found to be less resistant for imipenem (13.2%), ceftriaxone (31.6%), and ciprofloxacin (36.8%).
conclusionE. coli and K. pneumoniae from the clinical isolates displayed high resistance to many antibiotics in UTI patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.